Hideki Nakamura

Dr. Hideki Nakamura

Nagasaki University Graduate School of Biomedical Sciences

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
Hideki NakamuraHideki Nakamura
Hideki Nakamura
TUT. Usa
T. Usa
MMM. Motomura
M. Motomura
TIT. Ichikawa
T. Ichikawa
KNK. Nakao
K. Nakao
KEK. Eguchi
K. Eguchi

Verified
Journal Article
Open access
PDF file
STShimizu, Toshimasa
Shimizu, Toshimasa
Hideki NakamuraHideki Nakamura
Hideki Nakamura
AKAtsushi Kawakami
Atsushi Kawakami
Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation of the salivary and lacrimal glands and extra-glandular lesions. Adaptive immune response including T- and B-cell activation contributes to the development of SS. However, its pathogenesis has not yet been elucidated. In addition, several patients with SS present with the type I interferon (IFN) signature, which is the upregulation of the IFN-stimulated genes induced by type I IFN. Thus, innate immune responses including type I IFN activity are associated with SS pathogenesis. Recent studies have revealed the presence of activation pattern recognition receptors (PRRs) including Toll-like receptors, RNA sensor retinoic acid-inducible gene I and melanoma differentiation-associated gene 5, and inflammasomes in infiltrating and epithelial cells of the salivary glands among patients with SS. In addition, the activation of PRRs via the downstream pathway such as the type I IFN signature and nuclear factor kappa B can directly cause organ inflammation, and it is correlated with the activation of adaptive immune responses. Therefore, this study assessed the role of the innate immune signal pathway in the development of inflammation and immune abnormalities in SS.

21 July 2020 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
STShimizu, Toshimasa
Shimizu, Toshimasa
TKTomohiro Koga
Tomohiro Koga
KFK. Furukawa
K. Furukawa
YHY. Horai
Y. Horai
KFK. Fujikawa
K. Fujikawa
AKA. Kawakami
A. Kawakami

17 November 2018 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
STShimizu, Toshimasa
Shimizu, Toshimasa
Hideki NakamuraHideki Nakamura
Hideki Nakamura
ATAyuko Takatani
Ayuko Takatani
MUMasataka Umeda
Masataka Umeda
YHYoshiro Horai
Yoshiro Horai
AKAtsushi Kawakami
Atsushi Kawakami

Verified
Journal Article
Open access
PDF file
Hideki NakamuraHideki Nakamura
Hideki Nakamura
YHYoshiro Horai
Yoshiro Horai
STShimizu, Toshimasa
Shimizu, Toshimasa
AKAtsushi Kawakami
Atsushi Kawakami
The pathogenesis of Sjögren’s syndrome (SS) involves multiple factors including genetic background, cell death, and exocrine dysfunction. We here discuss apoptotic control in exocrine glands in SS by showing various pro- and anti-apoptotic pathways. Although the membrane-bound and soluble form of the Fas/Fas ligand system is a leading player with activation of the death domain and caspase 8/3 cleavage, the role of soluble Fas/FasL (including its polymorphism) in apoptosis is controversial. The tumor necrosis factor related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of salivary gland epithelial cells (SGECs) involves a mitochondrial pathway that includes caspase 9 cleavage. The involvement of innate immunity cells such as toll-like receptors (TLRs) has been investigated; TLR2-4 and TLR7-9 are associated with the induction of inflammation in exocrine glands of SS patients. TLR3 has the potential to induce the apoptosis of SS patients’ SGECs. Linkage of epidermal growth factor (EGF) was shown in exocrine glands in SS, and it inhibited the Fas/FasL system with the help of cell-survival factors. TLR3 has dual actions to cause inflammation as well as apoptosis, which are inhibited by EGF. In conclusion, apoptosis in exocrine glands of SS patients is tightly controlled by balance of pro-apoptotic signals and growth factor.

29 August 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
NINaoki Iwamoto
Naoki Iwamoto
SFShoichi Fukui
Shoichi Fukui
ATAyuko Takatani
Ayuko Takatani
STShimizu, Toshimasa
Shimizu, Toshimasa
MUMasataka Umeda
Masataka Umeda
AKAtsushi Kawakami
Atsushi Kawakami
Fibroblast-like synovial cells (FLS) have multilineage differentiation potential including osteoblasts. We aimed to investigate the role of microRNAs during the osteogenic differentiation of rheumatoid arthritis (RA)-FLS. RA-FLS were differentiated in osteogenic medium for 21 days. Osteogenic differentiation was evaluated by alkaline phosphatase (ALP) staining and Alizarin Red staining. MicroRNA (miRNA) array analysis was performed to investigate the differentially expressed miRNAs during osteogenic differentiation. Expression of miR-218-5p (miR-218) during the osteogenic differentiation was determined by quantitative real-time PCR. Transfections with an miR-218 precursor and inhibitor were used to confirm the targets of miR-218 and to analyze the ability of miR-218 to induce osteogenic differentiation. Secreted Dickkopf-1 (DKK1) from FLS transfected with miR-218 precursor/inhibitor or roundabout 1 (ROBO1) knockdown FLS established using ROBO1-small interfering RNA (siRNA) were measured by ELISA. The miRNA array revealed that 12 miRNAs were upregulated and 24 miRNAs were downregulated after osteogenic differentiation. We observed that the level of miR-218 rose in the early phase of osteogenic differentiation and then decreased. Pro-inflammatory cytokines modified the expression of miR-218. The induction of miR-218 in RA-FLS decreased ROBO1 expression, and promoted osteogenic differentiation. Both the overexpression of miR-218 and the knockdown of ROBO1 in RA-FLS decreased DKK1 secretion. We identified miR-218 as a crucial inducer of the osteogenic differentiation of RA-FLS. MiR-218 modulates the osteogenic differentiation of RA-FLS through the ROBO1/DKK-1 axis. The induction of the osteogenic differentiation of proliferating RA-FLS through the provision of miR-218 into RA-FLS or by boosting the cellular reservoir of miR-218 might thus become a therapeutic strategy for RA.